Ultra Wellness Utah

Semaglutide research education entry

GLP-1 receptor agonist studied in the STEP and SELECT Phase 3 clinical trial programs for metabolic support.

About this page

Semaglutide is the most clinically validated GLP-1 receptor agonist available, with Phase 3 STEP trial data showing mean weight reductions of 14.9% at 68 weeks. It has also demonstrated cardiovascular benefits in the SELECT trial. Its once-weekly dosing and extensive safety profile make it a foundational metabolic wellness compound.

Category: Weight Management & Metabolic Health. View the linked research sources and related educational resources for additional context.